NHLBI Resumes Participant Enrollment in Sickle Cell Disease Study

NHLBI Resumes Participant Enrollment in Sickle Cell Disease Study

Update: Statement on NHLBI decision to resume participant enrollment in the Pilot and Feasibility Study of Hematopoietic Stem Cell Gene Transfer for Sickle Cell Disease On February 17, 2021, out of an abundance of caution and concern for patient safety, the National Heart, Lung, and Blood Institute (NHLBI), part of NIH, placed an administrative hold on an NHLBI-funded trial at the Boston Children's Hospital, the Pilot and Feasibility Study of Hematopoietic Stem Cell Gene Transfer for Sickle Cell Disease. Following a review of the recommendation of the NHLBI Gene and Cell Therapy Data and Safety Monitoring Board (DSMB), which was informed by a thorough examination of safety information and extensive expert consultations, NHLBI lifted the study's administrative hold and resumed enrollment on December 1, 2021.  Read More

STAY CONNECTED      Questions? Contact us Manage Subscriptions or Account Preferences  |  Delete Account  |  Help The "Delete Account" link will unsubscribe you from every topic and delete your email address from the system.  To unsubscribe from select topics, click on "Manage Subscriptions or Account Preferences." If you have questions or comments about other NHLBI programs or activities, please contact nhlbiinfo@nhlbi.nih.gov or 1-877-NHLBI4U (877-645-2448). This service is provided to you at no charge by the National Heart, Lung, and Blood Institute, part of the National Institutes of Health.

---

GovDelivery, Inc. sending on behalf of The National Heart, Lung, and Blood Institute · P.O. Box 30105 · Bethesda, MD 20824 · 301-592-8573 TTY: 240-629-3255